Compare TTC & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTC | KYMR |
|---|---|---|
| Founded | 1914 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tools/Hardware | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.6B |
| IPO Year | 1994 | 2020 |
| Metric | TTC | KYMR |
|---|---|---|
| Price | $100.06 | $125.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 26 |
| Target Price | $104.00 | ★ $107.72 |
| AVG Volume (30 Days) | 525.9K | ★ 647.8K |
| Earning Date | 06-04-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.18 | N/A |
| Revenue | ★ $2,618,650,000.00 | $39,211,000.00 |
| Revenue This Year | $6.13 | $10.61 |
| Revenue Next Year | $4.45 | $8.17 |
| P/E Ratio | $45.67 | ★ N/A |
| Revenue Growth | ★ 4.53 | N/A |
| 52 Week Low | $67.64 | $39.84 |
| 52 Week High | $105.19 | $130.05 |
| Indicator | TTC | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 61.07 | 63.88 |
| Support Level | $91.43 | $76.40 |
| Resistance Level | $101.31 | $130.05 |
| Average True Range (ATR) | 2.05 | 4.72 |
| MACD | 0.13 | 0.95 |
| Stochastic Oscillator | 86.35 | 86.54 |
The Toro Co designs, manufactures, markets, and sells professional turf maintenance equipment and services; turf and agricultural irrigation systems; landscaping equipment and lighting products; snow and ice management equipment; construction equipment; and residential yard and snow thrower products. The company operates through Professional and Residential segments, with the Professional segment serving commercial, agricultural, and construction customers and generating the majority of revenue, while the Residential segment focuses on homeowners. Its products are sold through distributors, dealers, retailers, rental centers, and direct channels, with the United States as its primary revenue-generating market.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.